Many women are diagnosed with ovarian cancer at a later-stage of disease, when the potential for cure is limited.
Choice of first-line therapy is critical to optimizing patient outcomes.
Recent phase III clinical trials have reported important data about the role of PARP inhibitors in first-line treatment.
Women with disease that is BRCA ½ mutant and/or homologous repair deficient may benefit from first-line therapy including maintenance with a PARP inhibitor.
Clinicians must be familiar with the most up-to-date data about optimizing first-line therapy for their patients with advanced ovarian cancer.
Important Considerations in Choosing Therapy for Advanced Ovarian Cancer